Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.

Rus, C; Bazzan, M; Palumbo, A; Bringhen, S; Boccadoro, M

Rus, C; Bazzan, M; Palumbo, A; Bringhen, S; Boccadoro, M.

J Thromb Haemost ; 2(11): 2063-5, 2004 Nov.

Article in En | MEDLINE | ID: mdl-15550053

Subject(s)

Multiple Myeloma/complications; Multiple Myeloma/drug therapy; Thalidomide/adverse effects; Thalidomide/therapeutic use; Venous Thrombosis/chemically induced; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Fibrinolytic Agents/therapeutic use; Humans; Risk Factors; Thromboembolism/chemically induced; Thromboembolism/prevention & control; Treatment Outcome; Venous Thrombosis/prevention & control

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Venous Thrombosis / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies Limits: Aged / Humans Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2004 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links